Pharmacokinetics and Bioequivalence Estimation of Two Formulations of Alfuzosin Extended‐Release Tablets

Al Bawab, Abdel Qader, Alkhalidi, Bashar A., Albarahmieh, Esra'a, Qassim, Sami M.A., Al‐Saifi, Mohammad A.D., Al‐Saifi, Bashar, Ling, Jonathan and Al-Qerem, Waleed (2020) Pharmacokinetics and Bioequivalence Estimation of Two Formulations of Alfuzosin Extended‐Release Tablets. Clinical Pharmacology in Drug Development. ISSN 2160-763X

[img] Microsoft Word
203631_1_Alfazusinpaper_final_IJCP_CORRECTED.docx - Accepted Version
Restricted to Repository staff only until 16 July 2021.
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (41kB) | Request a copy

Search Google Scholar

Abstract

Alfuzosin is a medication approved by the US Food and Drug Administration to treat benign prostatic hyperplasia symptoms. Bioequivalence studies are demanded by regulatory authorities to evaluate the expected in vivo biological similarity of 2 formulations of a medication. The aim of this study is to assess the bioavailability of the generic (test) and branded (reference) formulations of 10‐mg alfuzosin extended‐release tablets after oral administration to healthy adults under fed conditions. The study used a comparative randomized, single‐dose, 2‐way crossover open‐label study design. Thirty‐three participants were recruited and completed the clinical assessment. The pharmacokinetic parameters maximum plasma concentration (Cmax), area under the plasma concentration–time curve (AUC0‐t), AUC extrapolated to infinity (AUC0‐∞), time to maximum concentration, and elimination half‐life were estimated to prove bioequivalence. The confidence intervals for the log‐transformed test/reference ratios for alfuzosin 110.7% (98.0–124.9) and 112.0% (101.9–123.1) for Cmax and AUC0‐t respectively, which are within the allowed limits specified by the regulatory authorities (80–125% for Cmax and AUC0‐t). The test formulation can therefore be prescribed as an alternative to the reference for symptomatic treatment of benign prostatic hyperplasia.

Item Type: Article
Subjects: Sciences > Pharmacy and Pharmacology
Divisions: Faculty of Health Sciences and Wellbeing
Depositing User: Jonathan Ling
Date Deposited: 17 Jul 2020 08:29
Last Modified: 18 Aug 2020 09:34
URI: http://sure.sunderland.ac.uk/id/eprint/12256
ORCID for Jonathan Ling: ORCID iD orcid.org/0000-0003-2932-4474

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year